229 In the index

Pegvisomant PEGV

An FDA-approved medication (Somavert) that blocks growth hormone's action, used for the hormone disorder acromegaly when other treatments haven't worked. Human studies confirm it effectively controls the excess-hormone effects, though liver function needs to be monitored during use.

Also known as Somavert

Effects Hormonal

Routes Subcutaneous

Legal status Prescription drug

WADA Not listed

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 10 mg/day (after loading dose), titrated by IGF-1 levels

Reported range 10-30 mg/day

Route Subcutaneous injection

Frequency Once daily

Duration Chronic/ongoing (as prescribed)

FDA-approved growth-hormone receptor antagonist (Somavert) for acromegaly.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.